Company: AstraZeneca ( AZN)

Drug/indication: Zibotentan for prostate cancer

Estimated timing: Fourth quarter

Recent stock performance: A rebound in June and July has pushed the stock up 6% for the year.

Zibotentan represents the biggest, near-term competitive threat to Dendreon's ( DNDN) prostate cancer immunotherapy Provenge. The phase III study of zibotentan targets the same patient population described in Provenge's FDA-approved label -- men with prostate cancer that no longer respond to hormone treatment but who have minimal bone pain and have not yet started chemotherapy.

The study of 580 men compares treatment with zibotentan against best supportive care with a primary endpoint of overall survival. If the study is positive and zibotentan gains FDA approval, doctors will have another treatment choice besides Provenge for this group of prostate cancer patients.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)